Urologix, Inc. (NasdaqCM:ULGX) entered into an asset purchase agreement and license agreement to acquire certain assets related to Prostiva business from Medtronic VidaMed, Inc. for $7.5 million on September 6, 2011. The purchase price is payable the later of September 6, 2012 or at the closing of the transaction. On June 28, 2013, Urologix entered into amendment agreements. Of the purchase price $2 million is paid in cash and balance as notes. The transaction is subject to approval of US regulatory authorities, execute and deliver to Medtronic the note, transitional service agreement, security agreement and subordination agreement with Silicon Valley Bank. Charles P. Moorse and Barbara Rummel of Lindquist & Vennum P.L.L.P. acted as legal advisors for Urologix. Robert A. Kukuljan of Stoel Rives LLP acted as legal advisor to Medtronic VidaMed, Inc. KPMG LLP acted as accountant to Urologix.

Urologix, Inc. (NasdaqCM:ULGX) completed the acquisition of certain assets and license related to Prostiva business from Medtronic VidaMed, Inc. on August 20, 2013.